Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Acquired by Millennium Management LLC

Millennium Management LLC grew its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 22.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 896,987 shares of the biotechnology company's stock after acquiring an additional 165,692 shares during the period. Millennium Management LLC owned about 4.21% of Enanta Pharmaceuticals worth $5,158,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Enanta Pharmaceuticals during the 4th quarter worth about $26,000. Tower Research Capital LLC TRC increased its holdings in shares of Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock worth $41,000 after buying an additional 2,274 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $58,000. Wells Fargo & Company MN increased its holdings in shares of Enanta Pharmaceuticals by 69.6% during the 4th quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company's stock worth $91,000 after buying an additional 6,518 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of Enanta Pharmaceuticals during the 4th quarter worth approximately $105,000. Institutional investors and hedge funds own 94.99% of the company's stock.

Enanta Pharmaceuticals Price Performance

Shares of NASDAQ ENTA traded up $0.36 on Monday, hitting $6.29. The company's stock had a trading volume of 121,725 shares, compared to its average volume of 285,196. Enanta Pharmaceuticals, Inc. has a 12-month low of $4.09 and a 12-month high of $17.24. The company has a market capitalization of $134.46 million, a price-to-earnings ratio of -1.27 and a beta of 0.81. The stock has a 50 day moving average of $5.40 and a 200-day moving average of $6.21.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The business had revenue of $14.93 million during the quarter, compared to analysts' expectations of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. Sell-side analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ENTA. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Wall Street Zen raised shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Wednesday, February 19th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $17.25.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.